Skip to main
ACIU
ACIU logo

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is advancing its clinical-stage pipeline focused on neurodegenerative diseases, with a particular emphasis on therapeutics and diagnostics targeting misfolded proteins. The positive outlook is bolstered by significant developments such as the upcoming EVOKE trial for AD patients, which could dramatically enhance interest in the NLRP3 program, and encouraging results from the PD active immunotherapy ACI-7104.056, which has exhibited a 20-fold increase in antibodies against pathogenic variants of alpha-synuclein, thereby positioning the company favorably within a growing treatment landscape for Alzheimer’s disease.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, indicating financial distress and potential challenges in sustaining operations. The company is exposed to significant industry risks, including the possibility of adverse clinical trial outcomes, regulatory hurdles, and the complexities of navigating price-sensitive markets for its product candidates. These factors contribute to a precarious financial outlook, raising concerns about the company's ability to effectively advance its pipeline of therapies and diagnostic products targeting neurodegenerative diseases.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.